摘要
目的探讨FibroScan(FS)在慢性乙型肝炎(CHB)急性发作期患者中的改变及其应用价值。方法选择2009年1月～2012年6月在我院住院的187例CHB急性发作期患者,对其进行拉米夫定联合阿德福韦酯抗病毒以及护肝等治疗,治疗前后进行肝功能、HBV DNA、血清肝纤维化指标检测以及FS检查,并分析FS的相关影响因素。结果经过6个月的治疗后,患者肝功能相关指标、HBV DNA、血清肝纤维化指标以及FS值均较治疗前有显著性改善,且FS值与肝功能、HBV DNA、血清肝纤维化指标呈显著正相关。结论 CHB急性发作期患者的FS值受肝功能以及HBV DNA水平的影响,积极抗病毒治疗可以降低CHB患者的肝纤维化程度。
Objective To investigate the changes and application values of FibroScan （FS） in patients with acute at tack of chronic hepatitis B （CHB）. Methods All of 187 patients with acute attack of CHB from January 2009 to June 2012 were analyzed retrospectively. All patients were used lamivudine combined with adefovir in antiviral therapy, and detected liver function, HBV-DNA, liver fiber spectrum and FibroScan after treatment, then analyse of the related in- fluencing factors of FibroScan. Results Liver function,liver fiber spectrum and HBV-DNA were significantly＇different in FS values after 6 months, those showed significant positive correlation. Conclusion FibroScan was used to diagnose chronic hepatitis B in acute attack, and affected by liver function and HBVDNA. Positive anti-hepatitis B virus thera- py can decrease in patients with chronic hepatitis B liver stiffness.
出处
《中国现代医生》
2013年第11期36-37,39,共3页
China Modern Doctor
基金
中国肝炎防治基金会王宝恩肝纤维化研究基金(No.20100009)
